• SCH772984 HCl: ERK1/2 Assay Guide

  2026-08-22

  A scenario-based guide to using SCH772984 HCl (SKU B5866) for ERK1/2 pathway interrogation, cell proliferation studies, and cytotoxicity assay interpretation. It covers concentration selection, solvent handling, orthogonal readouts, stem-cell research limitations, and practical product-selection criteria.

• Honokiol: From Mechanism to Translational Strategy

  2026-08-21

  Honokiol offers translational researchers a mechanistically rich way to connect NF-κB signaling, oxidative stress, inflammation, tumor biology, and assay interpretation. This article moves beyond a conventional product overview by integrating compound handling with orthogonal viability, cell-death, and pathway readouts informed by the Schwartz dissertation.

• Dabigatran etexilate: Assay Workflows

  2026-08-20

  Build a translational coagulation workflow around Dabigatran etexilate, from thrombin target engagement to plasma clotting and platelet responses. The guide emphasizes prodrug-aware assay design, practical controls, and troubleshooting for atrial fibrillation and broader anticoagulant research.

• ST3GAL1 Sialylation Drives F. nucleatum Adhesion

  2026-08-20

  The reference study identifies ST3GAL1-dependent host-cell sialylation as a determinant of Fusobacterium nucleatum adhesion to colorectal cancer cells. Its findings connect bacterial retention with an H3K27ac–ANGPTL4 program, providing a mechanistic framework for understanding how tumor glycosylation may support intratumoral microbial persistence.

• Norepinephrine Formulation Reporting in Critical Care

  2026-08-19

  The SCCM-ESICM joint task force identified clinically important variation in how norepinephrine is labeled and reported as a conjugated salt or active base. Its position paper argues that formulation identity and base-equivalent dose should be standardized to improve patient safety, trial enrollment, and cross-country interpretation of vasopressor datasets.

• BMS 599626 Dihydrochloride: EGFR/ErbB2 Inhibitor

  2026-08-19

  BMS 599626 dihydrochloride is an EGFR and ErbB2 inhibitor for preclinical studies of receptor phosphorylation, cancer cell proliferation inhibition, and xenograft tumor growth. Supplier-reported kinase potency and lung tumor xenograft findings support its use as a selective EGFR/HER2 signaling probe, not as a diagnostic or medical product.

• Dacarbazine: Bench Workflows for DNA Damage Studies

  2026-08-18

  Learn how to use Dacarbazine in reproducible cytotoxicity, proliferation, and DNA damage experiments rather than treating viability loss as a single endpoint. The workflow also shows how supportive-care evidence on palonosetron can inform translational study design without overstating what the reference proves.

• PAD4-IN-2 TFA: Tumor-Targeted PAD4 Inhibition

  2026-08-18

  PAD4-IN-2 TFA, also called Compound 5i TFA, is a meta-phenylboronic acid-modified PAD4 inhibitor designed for tumor-biased uptake. Preclinical studies link it to reduced histone H3 citrullination, neutrophil extracellular trap formation, tumor growth, and lung metastasis with favorable mouse safety markers.

• Topotecan HCl: Reading Death Beyond Viability

  2026-08-17

  Topotecan HCl is a topoisomerase 1 inhibitor whose apparent potency depends on how growth arrest, cell killing, and exposure time are measured. This guide applies a dissertation-derived framework to improve assay design, model selection, and interpretation of Topotecan HCl responses.

• Palmitic acid (N2456): Protocol and QC Guide

  2026-08-17

  Palmitic acid (SKU N2456), also called hexadecanoic acid, provides a defined saturated long-chain fatty acid for solvent-controlled in vitro studies of lipid metabolism, protein palmitoylation, and related signaling workflows. It should not be selected for aqueous-only protocols or for experiments that require long-term storage of prepared solutions.

• Vemurafenib: Designing Better Melanoma Assays

  2026-08-16

  Vemurafenib and PLX4032 are valuable tools for modeling BRAF-driven melanoma biology. This guide shows how to connect early signaling, resistance phenotypes, and multi-omics evidence to make more informative cancer biology assays.

• Thymoquinone Protects Against Doxorubicin Cardiotoxicity

  2026-08-15

  A 2025 mouse study identifies thymoquinone as a potential countermeasure against doxorubicin-induced cardiac injury, linking functional protection with Nrf2/HO-1 activation, improved antioxidant status, and reduced ferroptosis-associated damage. Its findings provide a mechanistic foundation for preclinical cardiotoxicity research while leaving pathway causality, pharmacokinetics, and preservation of doxorubicin antitumor activity for future studies.

• Bufalin Targets STK33 in Triple-Negative Breast Cancer

  2026-08-14

  A 2025 Advanced Science study identifies serine/threonine kinase 33 (STK33) as a direct, degradation-sensitive target of the cardiotonic steroid Bufalin in triple-negative breast cancer. By combining chemical-proteomic target discovery, biophysical binding assays, genetic perturbation, animal models, and patient-derived organoids, the work connects Bufalin–STK33 engagement to disruption of an STK33–HSP90 stability mechanism and suppression of tumor growth.

• TMJ Inflammation, Microglia, and Synaptic Pruning

  2026-08-14

  This study identifies a mechanistic pathway linking temporomandibular joint inflammation to hippocampal microglial activation, neuronal C3 deposition, excessive synaptic pruning, and depression-like behaviors in mice. Its perturbation-based design highlights microglial Nr4a1 and neuronal C3 as experimentally testable nodes while clarifying the limits of translating these findings to other inflammatory signaling models.

• In Vitro Cancer Drug Response: Growth vs Death

  2026-08-13

  Hannah R. Schwartz’s dissertation distinguishes relative viability from fractional viability when measuring anticancer drug responses in vitro. The framework shows that growth inhibition and cell death are related but non-equivalent outcomes, supporting more informative assay design and interpretation.

8628 records 1/576 page Next 12345 下5页 Last page